News | October 08, 2014

Twelve-month Data From St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety, Efficacy

St. Jude Medical presents data for patients with drug-resistant uncontrolled hypertension at TCT 2014

Twelve-month Data St. Jude Medical EnligHTN Renal Denervation System

October 8, 2014 — St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Renal denervation is a specialized ablation procedure that has demonstrated a reduction in blood pressure for patients with hypertension, or high blood pressure, that is resistant to medical therapy. The EnligHTN system delivers radiofrequency (RF) energy from an ablation catheter to create lesions (tiny scars) along the renal nerves — a network of nerves in the walls of the renal arteries thought to help control blood pressure. The intentional disruption of the nerve supply has been found to help reduce systolic and diastolic blood pressure. The system catheter has a unique, non-occlusive basket design with multiple electrodes, which help physicians deliver a predictable treatment pattern while allowing for continuous blood flow to the kidney throughout the procedure. The next-generation EnligHTN system, CE Mark approved in 2013, delivers simultaneous ablations via a multi-electrode catheter, reducing total ablation time by more than 80 percent in comparison to the first generation system, from approximately 24 minutes to four minutes.

“The 12-month data for EnligHTN III continues to show the benefits of the EnligHTN Renal Denervation System and merits for its potential to change the way hypertension is treated,” said Prof. Stephen Worthley of St. Andrew's Hospital in Adelaide, Australia, a principal investigator of the EnligHTN III study. “These data continue to demonstrate that the multi-electrode system from St. Jude Medical provides a safe and effective alternative for patients with drug-resistant and uncontrolled hypertension.”

The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes at six centers through twelve months of follow-up for 37 eligible patients.

Twelve-month EnligHTN III data showed:

  • An average office systolic blood pressure reduction of 23 mmHg points
  • An average ambulatory systolic blood pressure reduction of 10 mmHg points
  • 78 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit

“We are pleased with the progress of our EnligHTN Renal Denervation program,” said Mark D. Carlson, chief medical officer for St. Jude Medical. “Our innovative EnligHTN technology with its multiple electrode basket design allows for consistent lesion creation that we believe minimizes variability during the procedure.”

The EnligHTN III study expands upon the research conducted in the EnligHTN I trial of the first-generation EnligHTN system, which demonstrated that patients with drug-resistant hypertension had a safe drop in blood pressure.

For more information: sjm.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init